SPARK Educational Forum (2017): Clinical Trial Design

Endpoint Selection in Early Clinical Trials

Prof. Frank Wagner, CRO
Clinical Trial Design

Prof. Franz Theuring, Charité
Treatment of Alzheimer Disease: Clinical Trial Designs for Tau-Aggregation-Inhibitors What is critical when designing Clinical Trials

How are relevant endpoints chosen? In the first lecture we will learn about clinical trial design, endpoint selection and potential pitfalls associated with this. Prof. Wagner, head of CRO Charité, has been actively involved in planning and setting institutional frameworks for conduct of clinical trials and will give an overview on clinical trial design with a special focus on endpoint selection.

In the second lecture, Prof. Theuring will talk about clinical trials from his own experience and co-founded company TauRx-Pharma, which has developed Tau-aggregation-inhibitors to treat Alzheimers disease. Prof. Theuring is an acknowledged expert in employing transgenic technologies to study gene regulation, gene function and establishment of animal models for human disease. He has many years of experience from industry (Schering) and holds a professorship of molecular pharmacology at the Charité since 1996.